Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Study of Tadalafil Once-Daily in Asian Men With Benign Prostatic Hyperplasia (BPH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Present with benign prostatic hyperplasia (BPH; also referred to as BPH-LUTS), based on the disease diagnostic criteria, at study entry.~* Provide signed informed consent at study entry.~* Have BPH-LUTS with a Total International Prostate Symptom Score (IPSS) of ≥13 at beginning of placebo lead-in period.~* Have bladder outlet obstruction of intermediate severity as defined by a urinary peak flow rate (Qmax) of ≥4 to ≤15 milliliters per second (mL/sec) \[from a prevoid total bladder volume (assessed by ultrasound) of ≥150 to ≤550 milliliters (mL) and a minimum voided volume of 125 mL\] at beginning of placebo lead-in period.~* Have prostate volume ≥20 mL estimated by transabdominal or transrectal ultrasound at study entry.~* Agree not to use any other approved or experimental pharmacologic BPH, erectile dysfunction (ED) and/or overactive bladder (OAB) treatments, including alpha-blockers, 5-alpha reductase inhibitors (5-ARIs), phosphodiesterase type 5 (PDE5) inhibitors, or herbal preparations at any time during the study.~* Have not taken the following treatments within the indicated duration:~  * Finasteride therapy for at least 3 months prior to beginning of placebo lead-in period.~ * Dutasteride therapy for at least 6 months prior to beginning of placebo lead-in period.~ * Anti-androgenic hormone therapy at least 12 months prior to beginning of placebo lead-in period.~ * All other BPH therapy (including herbal preparations) for at least 4 weeks prior to beginning of placebo lead-in period.~ * ED therapy for at least 4 weeks prior to beginning of placebo lead-in period.~ * OAB therapy for at least 4 weeks prior to beginning of placebo lead-in period.~* Demonstrate compliance with study drug administration requirements during the placebo lead-in period by administering ≥70% of prescribed doses, confirmed by documentation that the participant returned ≤30% of prescribed doses at randomization.~Exclusion Criteria:~* Prostate-specific antigen (PSA) \>10.0 nanograms per milliliter (ng/mL) at study entry.~* PSA ≥4.0 to ≤10.0 ng/mL at study entry, if prostate malignancy has not been ruled out to the satisfaction of an urologist.~* Bladder postvoid residual (PVR) ≥300 mL by ultrasound determination at study entry.~* History of any of the following pelvic conditions (checked at study entry):~  * Pelvic surgery or any other pelvic procedure, including radical prostatectomy, pelvic surgery for removal of malignancy, or bowel resection.~ * Pelvic radiotherapy.~ * Any pelvic surgical procedure on the urinary tract, including minimally invasive BPH-LUTS therapies and penile implant surgery.~ * Lower urinary tract malignancy or trauma.~* Lower urinary tract instrumentation (including prostate biopsy) within 30 day of study entry.~* History of urinary retention or lower urinary tract (bladder) stones within 6 months of study entry.~* History of urethral obstruction due to stricture, valves, sclerosis, or tumor.~* Current neurologic disease or condition associated with neurogenic bladder (for example, Parkinson's disease, multiple sclerosis) at study entry.~* Clinical evidence of prostate cancer.~* Clinical evidence of any of the following bladder conditions:~  * Mullerian duct cysts.~ * Atonic, decompensated, or hypocontractile bladder.~ * Detrusor-sphincter dyssynergia (contraction of the detrusor without sphincter relaxation).~ * Intravesical obstruction (for example, intravesical median lobe of the prostate).~ * Interstitial cystitis.~* Clinical evidence of any of the following urinary tract conditions at study entry:~  * Urinary tract infection.~ * Urinary tract inflammation (including prostatitis). Urinary tract infection/inflammation is defined as a positive result for leukocyte esterase from a urine dipstick or \>5 white blood cells (WBCs) per high-powered field on urinalysis from a centrifuged, clean-catch, midstream urine specimen.~ * Current antibiotic therapy for urinary tract infection.~ * Clinically significant microscopic hematuria as determined by an urologist.~* History of significant renal insufficiency, defined as receiving renal dialysis or having an estimated creatinine clearance \<30 milliliters per minute (mL/min) at study entry, as calculated by the central laboratory using the Cockcroft-Gault formula.~* Clinical evidence of severe hepatic impairment \[aspartate transaminase (AST) or alanine transaminase (ALT) \>3-fold of the upper limit of normal range\] at study entry.~* History of any of the following cardiac conditions (checked at study entry):~  * Angina requiring treatment with long-acting nitrates.~ * Angina requiring treatment with short-acting nitrates within 90 days of study entry.~ * Unstable angina within 90 days of study entry.~ * Positive cardiac stress test without documented evidence of subsequent, effective cardiac intervention.~* History of any of the following coronary conditions within 90 days of study entry:~  * Myocardial infarction.~ * Coronary artery bypass graft surgery.~ * Percutaneous coronary intervention (for example, angioplasty or stent placement).~* Any evidence of heart disease \[New York Heart Association (NYHA) ≥Class III\] within 6 months of study entry.~* Systolic blood pressure \>160 or \<90 millimeters of mercury (mm Hg) or diastolic blood pressure \>100 or \<50 mm Hg at study entry (if stress is suspected, retest under basal conditions), or malignant hypertension.~* Glycosylated hemoglobin (HbA1c) \>9% at study entry.~* Scheduled or planned surgery (or any procedure requiring general, spinal, or epidural anesthesia) during the course of the study.~* History of significant central nervous system injuries (including stroke or spinal cord injury) within 6 months of study entry.~* History of drug, alcohol, or substance abuse within 6 months of study entry.~* Current treatment with nitrates, androgens, antiandrogens, estrogens, luteinizing hormone-releasing hormone agonists/antagonists, or anabolic steroids at study entry.~* Current systemic treatment with any of the following:~  * Potent cytochrome P450 3A4 (CYP3A4) inhibitors, such as ketoconazole or ritonavir.~ * CYP3A4 inducers such as rifampicin.~* Known or suspected to be hypersensitive to tadalafil, or any study drug components.~* Any conditions that would interfere with a participant's ability to provide informed consent or comply with study instructions, would place participant at increased risk, or might confound the interpretation of the study results.~* Previously completed or withdrawn from this study or any other study investigating tadalafil.~* Received treatment within the last 30 days with a drug or device that has not received regulatory approval for any indications at the time of informed consent. Participants who have been screen failures in previous studies may be eligible.

- Gender: MALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Following the 4-week placebo lead-in period, this arm will consist of a 12-week placebo treatment period involving 2 x 2.5-milligram (mg) tadalafil placebo tablets taken orally once daily.
- Tadalafil (Type: EXPERIMENTAL): Following the 4-week placebo lead-in period, this arm will consist of a 12-week treatment period involving 2 x 2.5-mg tadalafil tablets taken orally once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).